Search research articles
Contact Us
Filters
Showing results (351-360 of 434) with videos related to
Page
of 44
Sort By:
Blood Advances
|
October 9, 2021
Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma
Chiara Pighi, Taek-Chin Cheong, Mara Compagno, et al.
International Journal of Cancer
|
June 12, 2013
Genome-wide methylation analyses identify a subset of mantle cell lymphoma with a high number of methylated CpGs and aggressive clinicopathological features
Anna Enjuanes, Robert Albero, Guillem Clot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 27, 2009
A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy
William W L Choi, Dennis D Weisenburger, Timothy C Greiner, et al.
Cancer Discovery
|
May 4, 2023
Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas
Sebastian Scheich, Jiji Chen, Jiamin Liu, et al.
Blood
|
January 9, 2014
Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue
David W Scott, George W Wright, P Mickey Williams, et al.
Leukemia
|
January 1, 2016
Recurrent activating mutations of CD28 in peripheral T-cell lymphomas
J Rohr, S Guo, J Huo, et al.
Cancer Cell
|
May 30, 2017
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma
Michail S Lionakis, Kieron Dunleavy, Mark Roschewski, et al.
Cell
|
July 4, 2020
TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate
Leandro Venturutti, Matt Teater, Andrew Zhai, et al.
Cancer Discovery
|
March 9, 2013
TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia
Takaomi Sanda, Jeffrey W Tyner, Alejandro Gutierrez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 7, 2017
A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Myron S Czuczman, Marek Trněný, Andrew Davies, et al.
Page
of 44
Search research articles
Search
Showing results (351-360 of 434) with videos related to
Sort By:
Page
of 44
Blood Advances
|
October 9, 2021
Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma
Chiara Pighi, Taek-Chin Cheong, Mara Compagno, et al.
International Journal of Cancer
|
June 12, 2013
Genome-wide methylation analyses identify a subset of mantle cell lymphoma with a high number of methylated CpGs and aggressive clinicopathological features
Anna Enjuanes, Robert Albero, Guillem Clot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 27, 2009
A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy
William W L Choi, Dennis D Weisenburger, Timothy C Greiner, et al.
Cancer Discovery
|
May 4, 2023
Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas
Sebastian Scheich, Jiji Chen, Jiamin Liu, et al.
Blood
|
January 9, 2014
Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue
David W Scott, George W Wright, P Mickey Williams, et al.
Leukemia
|
January 1, 2016
Recurrent activating mutations of CD28 in peripheral T-cell lymphomas
J Rohr, S Guo, J Huo, et al.
Cancer Cell
|
May 30, 2017
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma
Michail S Lionakis, Kieron Dunleavy, Mark Roschewski, et al.
Cell
|
July 4, 2020
TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate
Leandro Venturutti, Matt Teater, Andrew Zhai, et al.
Cancer Discovery
|
March 9, 2013
TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia
Takaomi Sanda, Jeffrey W Tyner, Alejandro Gutierrez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 7, 2017
A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Myron S Czuczman, Marek Trněný, Andrew Davies, et al.
Page
of 44